1095010-44-8Relevant articles and documents
QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF
-
Paragraph 309, (2022/01/12)
Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.
BICYCLIC INHIBITORS OF PAD4
-
Paragraph 00140; 00249, (2017/07/06)
The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
SUBSTITUTED [1,2,4] TRIAZOLO [1,5-A] PYRIMIDIN-7-YL COMPOUNDS AS PDE2 INHIBITORS
-
, (2015/11/10)
The invention provides a chemical entity of Formula (I): wherein R1, R2, X, Y and Z have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of
SERINE/THREONINE KINASE INHIBITORS
-
Paragraph 00370, (2015/07/16)
Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
1,5-Substituted nipecotic amides: Selective PDE8 inhibitors displaying diastereomer-dependent microsomal stability
DeNinno, Michael P.,Wright, Stephen W.,Visser, Michael S.,Etienne, John B.,Moore, Dianna E.,Olson, Thanh V.,Rocke, Benjamin N.,Andrews, Melissa P.,Zarbo, Cynthia,Millham, Michele L.,Boscoe, Brian P.,Boyer, David D.,Doran, Shawn D.,Houseknecht, Karen L.
scheme or table, p. 3095 - 3098 (2011/06/24)
The first highly potent and selective PDE8 inhibitors are disclosed. The initial tetrahydroisoquinoline hit was transformed into a nipecotic amide series in order to address a reactive metabolite issue. Reduction of lipophilicity to address metabolic liab
